Trial Profile
A Fixed-Dose, Randomized, Double-Blind, Placebo-Controlled Study of LY2216684 in Pediatric Patients With Attention Deficit/Hyperactivity Disorder.
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Edivoxetine (Primary) ; Methylphenidate
- Indications Attention-deficit hyperactivity disorder
- Focus Registrational; Therapeutic Use
- Sponsors Eli Lilly and Company
- 24 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Nov 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 06 May 2010 Planned end date changed from 1 May 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov.